sparfloxacin
Sign in to saveAlso known as Spara, Zagam, cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, AT-4140, CI-978
Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile.
Research
1,325 papers- Sparfloxacin: a review.Clinical therapeutics · 2000
- Clinical pharmacokinetics of sparfloxacin.Clinical pharmacokinetics · 1993
- Levofloxacin and sparfloxacin: new quinolone antibiotics.The Annals of pharmacotherapy · 1998
- Sparfloxacin ameliorates DSS-induced ulcerative colitis by suppressing cellular senescence, JAK/NF-κB signaling pathway and modulation of the gut microbiota-metabolite axis.Biochemical pharmacology · 2025
- Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.Drugs · 1997
via PubMed
~5 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Adverse reactions
- Pharmacological properties
- Mechanism of action
- References
Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile.
It was patented in 1985 and approved for medical use in 1993. Zagam is no longer available in the United States.
Excerpted from Wikipedia’s “sparfloxacin” article, available under the CC BY-SA 4.0 licence.